Inclusion Criteria:

1. Histological confirmation (by biopsy or cytology) of primary NSCLC. The following
primary cancer types are eligible: squamous cell carcinoma, adenocarcinoma, large
cell carcinoma, bronchioloalveolar cell carcinoma, or non-small cell carcinoma not
otherwise specified

2. Centrally located, defined as located within 2 cm of the central bronchial tree
(carina, right and left main bronchi, right and left upper lobe bronchi, bronchus
intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe
bronchi), major vessels (aorta, pulmonary artery trunk, left/right pulmonary
artery/vein main branches, superior/inferior vena cava, brachiocephalic artery trunk
or left/right brachiocephalic vein, left/right subclavian artery/vein), esophagus,
heart, tracheal, pericardium, mediastinal pleural and brachial plexus and vertebral
body, but no direct invasion, Stage I (T1-T2a <= 5 cm without main bronchus
involvement), selective stage II ( selective T3 with involvement of mediastinal
pleura, parietal pericardium,) based upon the following minimum diagnostic workup:

3. continued from criteria #2) History/physical examination including weight and
assessment of Zubrod performance status within 2 months prior to registration;
Evaluation by an experienced thoracic cancer clinician within 2 months prior to
registration; computed tomography (CT) scan with intravenous contrast (unless
medically contraindicated) of the entirety of both lungs and the mediastinum, most
part of liver, and adrenal glands acquired within 2 months prior to registration must
be available. The primary tumor dimension will be measured on the CT. Whole body
fluorodeoxyglucose positron emission tomography (FDG-PET) within 3 months prior to
registration with adequate visualization of the primary tumor and draining lymph node
basins in the hilar and mediastinal regions and adrenal glands; Pulmonary function
tests (PFTs): Routine spirometry, lung volumes, diffusion capacity (within 3 months
prior to registration).

4. continued from inclusion #3) Patients with hilar or mediastinal lymph nodes and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients
with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including
suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy
of all abnormally identified areas are negative for cancer. The primary tumor should
be considered medically inoperable by an experienced thoracic cancer clinician for a
standard lobectomy and mediastinal lymph node dissection/sampling procedure or
patient refuses surgery. The patient may have underlying physiological medical
problems that would prohibit a surgery due to a low probability of tolerating general
anesthesia, the operation, the postoperative recovery period, or the removal of
adjacent functioning lung.

5. continued from inclusion #4) These types of patients with severe underlying health
problems are deemed "medically inoperable." Standard justification for deeming a
patient medically inoperable based on pulmonary function for surgical resection of
NSCLC may include any of the following: Baseline forced expiratory volume in 1 second
(FEV1) < 50% predicted, postoperative FEV1 < 30% predicted, severely reduced
diffusion capacity, baseline hypoxemia and/or hypercapnia, exercise oxygen
consumption < 50% predicted, severe pulmonary hypertension, diabetes mellitus with
severe end organ damage, severe cerebral, cardiac, or peripheral vascular disease, or
severe chronic heart disease. If the patient has medically resectable/operable
disease but declines surgery after consulting with a thoracic surgeon, he/she will be
considered eligible.

6. History of NSCLC treated with surgery and/or radiotherapy previously and disease has
been cured or clinically no disease progression for more than 6 months, now isolated
recurrent disease in lung parenchyma and without involvement of main bronchus, chest
wall, hilar/mediastinal lymph nodes and critical mediastinal structures. Biopsy of
recurrent disease is recommended.

7. Zubrod Performance Status 0-2;

8. Age >/= 18

9. Women of childbearing potential and male participants must agree to use a medically
effective means of birth control, such as condom/diaphragm and spermicidal foam,
intrauterine device (IUD), or prescription birth control pills, throughout their
participation in the treatment phase of the study.

10. The patient must provide study specific informed consent prior to study entry.

Exclusion Criteria:

1. Direct evidence of hilar or mediastinal lymph nodes or distant metastases after
appropriate staging studies.

2. Patients with active pulmonary or pericardial infection.

3. Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo
or fetus.

4. Patient pulmonary function showed that pre-bronchial dilator FEV1 <25% or DLCO<25%.

5. Patient currently requiring supplemental oxygen for his/her daily life.

6. Patient is pacemaker dependent.

7. Patients